The clock is quickly ticking down towards Hemispherx Biopharma's (NYSEMKT:HEB) Food and Drug Administration (FDA) December 20th meeting with the Arthritis Advisory Committee (NYSE:AAC) to discuss Ampligen's New Drug Application (NDA) for Chronic Fatigue Syndrome (CFS). As previously announced, the Prescription Drug User Fee Act (PDUFA) review goal for Ampligen is February 2nd, 2013.
The bulls and bears are thus having a vociferous argument over whether or not Ampligen will finally be approved this time around. With about a million people affected by CFS in the U.S. alone, an FDA approval of Ampligen could thus result in one of the more impressive share price appreciations in recent history. Specifically, HEB's current market cap of $116M ...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|